Clinical Trials Browser

OTHER × Ependymoma × Bevacizumab × Clear all

NCT01356290 2026-02-23

MEMMAT

Phase 2 Recruiting

Ependymoma, Medulloblastoma, Recurrence

NCT01125046 2021-01-22

Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas

Phase 2 Completed

50 enrolled 13 charts

Brain Neoplasms, Ependymoma, Meningioma, Neurofibromatosis 1, Neuroma, Acoustic, Neurofibromatosis 2

NCT00883688 2020-08-26

Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma

Phase 2 Completed

24 enrolled 5 charts

Brain Neoplasms, Ependymoma, Neuroectodermal Tumors, Primitive, Glioma, Subependymal

NCT01478321 2020-03-12

Efficacy of Hypofractionated XRT w/Bev. + Temozolomide for Recurrent Gliomas

Phase 2 Terminated

54 enrolled 10 charts

Astrocytoma, Ependymoma, Glioblastoma, Oligodendroglioma

NCT00352521 2014-07-22

Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) With Bevacizumab and Irinotecan for Malignant Glioma

Phase 2 Completed

Astrocytoma, Brain Neoplasms, Ependymoma, Glioblastoma, Glioma, Oligodendroglioma, Central Nervous System Neoplasms, Gliosarcoma

NCT00463203 2011-06-29

Bevacizumab and Irinotecan for Patients With Primary Brain Tumors and Progression After Standard Therapy

Phase 2 Completed

Brain Neoplasms, Ependymoma, Glioma, Recurrence